TITLE

Pharma sector wants only 62 drugs under monitoring mechanism

PUB. DATE
January 2007
SOURCE
Chemical Business;Jan2007, Vol. 21 Issue 1, p73
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on a report produced by the joint committee on Draft National Pharmaceutical Policy which deals with the drugs in the National List of Essential Medicine. Only 62 drugs of the 354 drugs were warranted by the pharmaceutical industry to come under price monitoring mechanism. Anti-cancer and antiretroviral are among the types of drugs that the industry did not want to be subjected to price control.
ACCESSION #
23954529

 

Related Articles

  • Grassley takes on drug prices. Mantone, Joseph // Modern Healthcare;8/2/2004, Vol. 34 Issue 31, p18 

    Reports on the efforts of U.S. Senate Finance Committee Chairman Chuck Grassley (R-Iowa) to regulate the pricing practices of pharmaceutical companies to help hospitals that may have been overcharged for drugs. Report on the 340B Drug Discount Program cited by Grassley in his letter addressed...

  • Is Health Reform About to Go the Way of No Child Left Behind? Huffington, Arianna // Progressive Populist;9/15/2009, Vol. 15 Issue 16, p9 

    The article discusses the author's insights regarding the deal of the U.S. federal government with big pharmaceutical companies to remove the ability of Medicare to negotiate for low prices of drugs. She argues that if there will be no drug prices negotiations, there will be no meaningful health...

  • South Africa: Searching for a New Model.  // Pharmaceutical Executive;Mar2006, Vol. 26 Issue 3, pS2 

    The article discusses the drug policies of the South African government at its effect to pharmaceutical companies. The authors informs that the South African government is pushing multinational companies to lower their prices of antiretroviral drugs or grant voluntary licenses to other companies...

  • High Drug Prices: For Research or Profit? Wolfe, Sidney // Pharmaceutical Executive;Mar2001, Vol. 21 Issue 3, p146 

    Focuses on several issues disputing the need for United States (U.S.) pharmaceutical companies to control drug prices in order to facilitate research for new treatments. Profit margin of U.S. pharmaceutical companies in 2000; Percentage of drug companies' budgets devoted to research and...

  • Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK. Borrell, J-R. // PharmacoEconomics;1999, Vol. 15 Issue 3, p291 

    Objective: This work carries out an empirical evaluation of the impact of the main mechanism for regulating the prices of medicines in the UK [the Pharmaceutical Price Regulation Scheme (PPRS)] on a variety of pharmaceutical price indices. The article also discusses to what extent...

  • Drug marketing practices facing new investigation.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p6 

    Focuses on the role of the U.S. Congress in investigating the marketing practices of pharmaceutical companies before enacting a Medicare drug benefit provision. Submission of written comments on the impact of marketing practices on drug costs; Implementation of government price control; Views...

  • O, CANADA! WHERE LOW DRUG PRICES ARE COSTLY TO YOUR HEALTH. Freese, Duane D. // Saturday Evening Post;Sep/Oct2003, Vol. 275 Issue 5, p38 

    Analyzes the disadvantage and danger posed by the lower drug prices in Canada. Comparison between the prices of drugs in Canada and the U.S.; Reasons for the difference between the prices in the two countries; Status of the pharmaceutical industry in Canada as of August 2003.

  • Readers Weigh In.  // Pharmaceutical Executive;Oct2015, Vol. 35 Issue 10, p10 

    Three letters to the editor are presented in response to the articles "The Pre-Gouging Price," "The Pathway to Public Rx Price Controls in 2016," and "Pharma Exec's 14th Annual Industry Audit."

  • Debate on drug prices in eastern Germany. Karcher, Helmut L. // BMJ: British Medical Journal (International Edition);2/2/91, Vol. 302 Issue 6771, p254 

    Debates on the regulation of drug prices in Eastern Germany. Price discount for drugs; Development of drug sales; Amount contributed by the pharmaceutical industry to compensate for the health insurance deficit.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics